Carmustine, etoposide, cytarabine and melphalan versus a newly designed intravenous busulfan-based Busulfex, etoposide and melphalan conditioning regimen for autologous hematopoietic cell transplant: a retrospective matched-pair analysis in advanced Hodgkin and non-Hodgkin lymphomas

References

• Jantunen E, Sureda A. The evolving role of stem cell transplants in lymphomas. Biol Blood Marrow Transplant 2012;18:660–673.
   PubMed Web of Science ®Google Scholar
• Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995;333:1540–1545.
   PubMed Web of Science ®Google Scholar
• Hagberg H, Gisselbrecht C. Randomised phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomisation to maintenance treatment with rituximab or not: an update of the CORAL study. Ann Oncol 2006;17(Suppl. 4):iv31–iv32.
   PubMedGoogle Scholar
• Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 2010;28:4184–4190.
   PubMed Web of Science ®Google Scholar
• Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 2002;359:2065–2071.
   PubMed Web of Science ®Google Scholar
• Linch DC, Winfield D, Goldstone AH, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 1993;341:1051–1054.
   PubMed Web of Science ®Google Scholar
• Phillips GL, Wolff SN, Herzig RH, et al. Treatment of progressive Hodgkin's disease with intensive chemoradiotherapy and autologous bone marrow transplantation. Blood 1989;73:2086–2092.
   PubMed Web of Science ®Google Scholar
• Reece DE, Barnett MJ, Connors JM, et al. Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol 1991;9:1871–1879.
   PubMed Web of Science ®Google Scholar
• Argiris A, Seropian S, Cooper DL. High-dose BEAM chemotherapy with autologous peripheral blood progenitor-cell transplantation for unselected patients with primary refractory or relapsed Hodgkin's disease. Ann Oncol 2000;11:665–672.
   PubMed Web of Science ®Google Scholar
• Chopra R, McMillan AK, Linch DC, et al. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients. Blood 1993;81:1137–1145.
   PubMed Web of Science ®Google Scholar
• van Besien K, Tabocoff J, Rodriguez M, et al. High-dose chemotherapy with BEAC regimen and autologous bone marrow transplantation for intermediate grade and immunoblastic lymphoma: durable complete remissions, but a high rate of regimen-related toxicity. Bone Marrow Transplant 1995;15:549–555.
   PubMed Web of Science ®Google Scholar
• Milpied N, Deconinck E, Gaillard F, et al. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 2004;350:1287–1295.
   PubMed Web of Science ®Google Scholar
• Ferme C, Mounier N, Divine M, et al. Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: results of the Groupe d’Etudes des Lymphomes de l’Adulte H89 Trial. J Clin Oncol 2002;20:467–475.
   PubMed Web of Science ®Google Scholar
• Valdez BC, Murray D, Nieto Y, et al. Synergistic cytotoxicity of the DNA alkylating agent busulfan, nucleoside analogs and suberoylanilide hydroxamic acid in lymphoma cell lines. Leuk Lymphoma 2012;53:973–981.
   PubMed Web of Science ®Google Scholar
• Valdez BC, Nieto Y, Murray D, et al. Epigenetic modifiers enhance the synergistic cytotoxicity of combined nucleoside analog-DNA alkylating agents in lymphoma cell lines. Exp Hematol 2012;40:800–810.
   PubMed Web of Science ®Google Scholar
• Bensinger WI. High-dose preparatory regimens. In: Appelbaum FR, Forman SJ, Negrin RS, et al., editors. Thomas’ hematopoietic cell transplantation. 4th ed. Chichester, UK: Wiley-Blackwell; 2009. pp 316–332.
   Google Scholar
• Sakellari I, Mallouri D, Constantinou V, et al. Busilvex in combination with etoposide and Melphalan as conditioning regimen in autologous haematopoietic cell transplantation for lymphomas: efficacy and safety. Bone Marrow Transplant 2012;47(Suppl.1): Abstract 450.
   Google Scholar
• Zhang H, Graiser M, Hutcherson DA, et al. Pharmacokinetic-directed high-dose busulfan combined with cyclophosphamide and etoposide results in predictable drug levels and durable long-term survival in lymphoma patients undergoing autologous stem cell transplantation. Biol Blood Marrow Transplant 2012;18:1287–1294.
   PubMed Web of Science ®Google Scholar
• Madden T, de Lima M, Thapar N, et al. Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: a comparison with an every 6-hour dosing schedule. Biol Blood Marrow Transplant 2007;13:56–64.
   PubMed Web of Science ®Google Scholar
• Grochow LB. Parenteral busulfan: is therapeutic monitoring still warranted? Biol Blood Marrow Transplant 2002;8:465–467.
   PubMed Web of Science ®Google Scholar
• Blume KG, Long GD, Negrin RS, et al. Role of etoposide (VP-16) in preparatory regimens for patients with leukemia or lymphoma undergoing allogeneic bone marrow transplantation. Bone Marrow Transplant 1994;14(Suppl. 4):S9–S10.
   PubMed Web of Science ®Google Scholar
• Appelbaum FR. Hematopoietic cell transplantation for non-Hodgkin's lymphoma: yesterday, today, and tomorrow. J Clin Oncol 2008;26:2927–2929.
   PubMed Web of Science ®Google Scholar
• Fernandez HF, Escalon MP, Pereira D, et al. Autotransplant conditioning regimens for aggressive lymphoma: are we on the right road? Bone Marrow Transplant 2007;40:505–513.
   PubMed Web of Science ®Google Scholar
• Shimoni A, Avivi I, Rowe JM, et al. A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma. Cancer 2012;118:4706–4714.
   PubMed Web of Science ®Google Scholar
• Salar A, Sierra J, Gandarillas M, et al. Autologous stem cell transplantation for clinically aggressive non-Hodgkin's lymphoma: the role of preparative regimens. Bone Marrow Transplant 2001;27: 405–412.
   PubMed Web of Science ®Google Scholar
• Reece DE, Nevill TJ, Sayegh A, et al. Regimen-related toxicity and non-relapse mortality with high-dose cyclophosphamide, carmustine (BCNU) and etoposide (VP16-213) (CBV) and CBV plus cisplatin (CBVP) followed by autologous stem cell transplantation in patients with Hodgkin's disease. Bone Marrow Transplant 1999;23:1131–1138.
   PubMed Web of Science ®Google Scholar
• Carella AM. Role of hematopoietic stem cell transplantation in relapsed/refractory hodgkin lymphoma. Mediterr J Hematol Infect Dis 2012;4:e2012059.
   PubMedGoogle Scholar
• Caballero MD, Rubio V, Rifon J, et al. BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors. Bone Marrow Transplant 1997;20:451–458.
   PubMed Web of Science ®Google Scholar
• Jo JC, Kang BW, Jang G, et al. BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: comparative analysis of efficacy and toxicity. Ann Hematol 2008;87:43–48.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Tani M, Gabriele A, et al. High-dose therapy with autologous transplantation for Hodgkin's disease: the Bologna experience. Haematologica 2003;88:522–528.
   PubMed Web of Science ®Google Scholar
• Akhtar S, El Weshi A, Abdelsalam M, et al. Primary refractory Hodgkin's lymphoma: outcome after high-dose chemotherapy and autologous SCT and impact of various prognostic factors on overall and event-free survival. A single institution result of 66 patients. Bone Marrow Transplant 2007;40:651–658.
   PubMed Web of Science ®Google Scholar
• Mills W, Chopra R, McMillan A, et al. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol 1995;13:588–595.
   PubMed Web of Science ®Google Scholar
• Cony-Makhoul P, Marit G, Boiron JM, et al. Busulphan and melphalan prior to autologous transplantation for myeloid malignancies. Bone Marrow Transplant 1995;16:69–70.
   PubMed Web of Science ®Google Scholar
• Aggarwal C, Gupta S, Vaughan WP, et al. Improved outcomes in intermediate- and high-risk aggressive non-Hodgkin lymphoma after autologous hematopoietic stem cell transplantation substituting intravenous for oral busulfan in a busulfan, cyclophosphamide, and etoposide preparative regimen. Biol Blood Marrow Transplant 2006;12:770–777.
   PubMed Web of Science ®Google Scholar
• Zaucha R, Gooley T, Holmberg L, et al. High-dose chemotherapy with BEAM or busulphan/melphalan and thiotepa followed by hematopoietic cell transplantation in malignant lymphoma. Leuk Lymphoma 2008;49:1899–1906.
   PubMed Web of Science ®Google Scholar
• Yusuf RZ, Dey B, Yeap BY, et al. Autologous SCT with a dose-reduced BU and CY regimen in older patients with non-Hodgkin's lymphoma. Bone Marrow Transplant 2009;43:37–42.
   PubMed Web of Science ®Google Scholar
• Escalon MP, Stefanovic A, Venkatraman A, et al. Autologous transplantation for relapsed non-Hodgkin's lymphoma using intravenous busulfan and cyclophosphamide as conditioning regimen: a single center experience. Bone Marrow Transplant 2009;44:89–96.
   PubMed Web of Science ®Google Scholar
• Kim JG, Sohn SK, Chae YS, et al. Multicenter study of intravenous busulfan, cyclophosphamide, and etoposide (i.v. Bu/Cy/E) as conditioning regimen for autologous stem cell transplantation in patients with non-Hodgkin's lymphoma. Bone Marrow Transplant 2007;40:919–924.
   PubMed Web of Science ®Google Scholar
• Musso M, Scalone R, Marcacci G, et al. Fotemustine plus etoposide, cytarabine and melphalan (FEAM) as a new conditioning regimen for lymphoma patients undergoing auto-SCT: a multicenter feasibility study. Bone Marrow Transplant 2010;45:1147–1153.
   PubMed Web of Science ®Google Scholar
• Ganguly S, Jain V, Divine C, et al. BU, melphalan and thiotepa as a preparative regimen for auto-transplantation in Hodgkin's disease. Bone Marrow Transplant 2012;47:311–312.
   PubMed Web of Science ®Google Scholar
• Di Ianni M, Ballanti S, Iodice G, et al. High-dose thiotepa, etoposide and carboplatin as conditioning regimen for autologous stem cell transplantation in patients with high-risk Hodgkin's lymphoma. Hematology 2012;17:23–27.
   PubMed Web of Science ®Google Scholar
• Visani G, Malerba L, Stefani PM, et al. BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients. Blood 2011;118:3419–3425.
   PubMed Web of Science ®Google Scholar
• Kebriaei P, Madden T, Kazerooni R, et al. Intravenous busulfan plus melphalan is a highly effective, well-tolerated preparative regimen for autologous stem cell transplantation in patients with advanced lymphoid malignancies. Biol Blood Marrow Transplant 2011;17:412–420.
   PubMed Web of Science ®Google Scholar
• Lill M, Costa LJ, Yeh RF, et al. Pharmacokinetic-directed dose adjustment is essential for intravenous busulfan exposure optimization: findings from a multi-center phase II study of autologous hematopoietic stem cell transplantation for lymphoma in North America. Biol Blood Marrow Transplant 2013;19(2 Suppl.):S132.
   Web of Science ®Google Scholar
• Nieto Y, Thall P, Valdez B, et al. High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignancies. Biol Blood Marrow Transplant 2012;18:1677–1686.
   PubMed Web of Science ®Google Scholar
• Wadehra N, Farag S, Bolwell B, et al. Long-term outcome of Hodgkin disease patients following high-dose busulfan, etoposide, cyclophosphamide, and autologous stem cell transplantation. Biol Blood Marrow Transplant 2006;12:1343–1349.
   PubMed Web of Science ®Google Scholar
• Bains T, Chen AI, Lemieux A, et al. Improved outcome with busulfan, melphalan and thiotepa conditioning in autologous hematopoietic stem cell transplant for relapsed/refractory Hodgkin lymphoma. Leuk Lymphoma 2014;55:583–587.
   PubMed Web of Science ®Google Scholar
• Nieto Y, Popat U, Anderlini P, et al. Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcome. Biol Blood Marrow Transplant 2013;19:410–417.
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C. Is there any role for transplantation in the rituximab era for diffuse large B-cell lymphoma? Hematology Am Soc Hematol Educ Program 2012;2012:410–416.
   PubMedGoogle Scholar
• Ulrickson M, Aldridge J, Kim HT, et al. Busulfan and cyclophosphamide (Bu/Cy) as a preparative regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma: a single-institution experience. Biol Blood Marrow Transplant 2009;15:1447–1454.
   PubMed Web of Science ®Google Scholar
• Kim JE, Lee DH, Yoo C, et al. BEAM or BuCyE high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: a single center comparative analysis of efficacy and toxicity. Leuk Res 2011;35:183–187.
   PubMed Web of Science ®Google Scholar
• van Kampen RJ, Canals C, Schouten HC, et al. Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin's lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry. J Clin Oncol 2011;29:1342–1348.
   PubMed Web of Science ®Google Scholar
• Robinson SP, Sureda A, Canals C, et al. Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcome. Haematologica 2009;94:230–238.
   PubMed Web of Science ®Google Scholar
• Kameoka Y, Takahashi N, Ishizawa K, et al. Safety and feasibility of high-dose ranimustine (MCNU), carboplatin, etoposide, and cyclophosphamide (MCVC) therapy followed by autologous stem cell transplantation for malignant lymphoma. Int J Hematol 2012;96: 624–630.
   PubMed Web of Science ®Google Scholar
• Lee SC, Kim SJ, Lee DH, et al. Excessive toxicity of once daily i.v. BU, melphalan and thiotepa followed by auto SCT on patients with non-Hodgkin's lymphoma. Bone Marrow Transplant 2010;45: 801–802.
   PubMed Web of Science ®Google Scholar
• Blijlevens N, Schwenkglenks M, Bacon P, et al. Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy—European Blood and Marrow Transplantation Mucositis Advisory Group. J Clin Oncol 2008;26:1519–1525.
   PubMed Web of Science ®Google Scholar
• Campbell P, Friebe A, Foulstone P, et al. Impact of palifermin on mucosal toxicity in autologous stem cell transplants using busulfan-melphalan conditioning chemotherapy for Hodgkin and non-Hodgkin lymphoma. Leuk Lymphoma 2012;53:1415–1416.
   PubMed Web of Science ®Google Scholar
• Lane AA, McAfee SL, Kennedy J, et al. High-dose chemotherapy with busulfan and cyclophosphamide and autologous stem cell rescue in patients with Hodgkin lymphoma. Leuk Lymphoma 2011;52: 1363–1366.
   PubMed Web of Science ®Google Scholar
• Roland V, Bodet-Milin C, Moreau A, et al. Impact of high-dose chemotherapy followed by auto-SCT for positive interim [18F] FDG-PET diffuse large B-cell lymphoma patients. Bone Marrow Transplant 2011;46:393–399.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579–586.
   PubMed Web of Science ®Google Scholar